Drugs / Sentagliptin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT07241897 | Dec 2025 → Dec 2027 expected | diabetes mellitus, ischemic stroke | Second Affiliated Hospital of Soochow University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sentagliptin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07241897 ↗ |
| Known as | Sentagliptin Phosphate | “Sentagliptin Phosphate 50 mg, once daily, plus metformin hydrochloride extended-release tablets (50 mg, two or three times daily). If blood glucose is still not...” NCT07241897 ↗ |